Cargando…

SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines

Detalles Bibliográficos
Autores principales:	Thiruvengadam, Ramachandran, Binayke, Akshay, Awasthi, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610239/ https://www.ncbi.nlm.nih.gov/pubmed/34826382 http://dx.doi.org/10.1016/S1473-3099(21)00697-6

Ejemplares similares

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world
por: Garg, Pramod Kumar, et al.
Publicado: (2022)

What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?
por: Wilder-Smith, Annelies
Publicado: (2022)

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India – Authors' reply
por: Thiruvengadam, Ramachandran, et al.
Publicado: (2022)

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections
por: Sigal, Alex, et al.
Publicado: (2022)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
por: Wang, Stephen Y, et al.
Publicado: (2022)

Persistence of IgG response to SARS-CoV-2
por: Duysburgh, Els, et al.
Publicado: (2021)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Clinical and experimental evidence suggest omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity
por: Thiruvengadam, Ramachandran, et al.
Publicado: (2023)

Decoding the next SARS-CoV-2 variant
por: Nel, Jeremy, et al.
Publicado: (2022)

Association of SARS-CoV-2 infection and persistence with long COVID
por: Yang, Chengliang, et al.
Publicado: (2023)

SARS-CoV-2 variants offer a second chance to fix vaccine inequities
por: Hotez, Peter J.
Publicado: (2022)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
por: Yadav, Pragya D, et al.
Publicado: (2022)

SARS-CoV-2 variants and ending the COVID-19 pandemic
por: Fontanet, Arnaud, et al.
Publicado: (2021)

COVID-19 vaccines in the age of the delta variant
por: Wheatley, Adam K, et al.
Publicado: (2022)

Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials
por: Moran, Ed, et al.
Publicado: (2021)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

SARS-CoV-2 evolution and vaccines: cause for concern?
por: Williams, Thomas C, et al.
Publicado: (2021)

Stroke after SARS-CoV-2 vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
por: Bird, Sarah, et al.
Publicado: (2021)

SARS-CoV-2 variants and considerations of inferring causality on disease severity
por: Cevik, Muge, et al.
Publicado: (2021)

Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits?
por: Hoehl, Sebastian, et al.
Publicado: (2023)

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
por: Shang, Weilong, et al.
Publicado: (2020)

SARS-CoV-2 vaccines: fast track versus efficacy
por: Alkandari, Dana, et al.
Publicado: (2021)

Single-dose SARS-CoV-2 vaccination efficacy in the elderly
por: Prendecki, Maria, et al.
Publicado: (2021)

Balancing risk and benefit of SARS-CoV-2 vaccines in children
por: Levin, Michael, et al.
Publicado: (2022)

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
por: Triccas, James A., et al.
Publicado: (2022)

Guillain-Barre syndrome related to SARS-CoV-2 vaccinations
por: Finsterer, Josef, et al.
Publicado: (2022)

SARS-CoV-2 vaccine strategies in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2023)

Stroke seven hours after SARS-CoV-2 vaccination
por: Fiorini, Ana Claudia, et al.
Publicado: (2023)

IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammation
por: Sadhu, Srikanth, et al.
Publicado: (2023)

Travel measures in the SARS-CoV-2 variant era need clear objectives
por: Kucharski, Adam J, et al.
Publicado: (2022)

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity
por: Markov, Peter V., et al.
Publicado: (2022)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

SARS-CoV-2 vaccination and phase 1 cancer clinical trials
por: Yap, Timothy A, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9jqiltm0seoqp6vl8ehkk97sgq